From a $1.8 Billion ADC Trio to a Unicycle: Rina-S Faces Major Challenges in 2024
Recently, Genmab quietly removed another ADC—GEN1160 (targeting CD70) from its clinical list, citing only one reason: “slow enrollment of participants.” This follows the announcement in September to abandon the PTK7 project GEN1107, marking the second “vessel” lost from the same $1.8 billion acquisition. As of now, the three clinical “tickets” sold to Genmab by ProfoundBio … Read more